Literature DB >> 2105500

Heritable major histocompatibility complex class II-associated differences in production of tumor necrosis factor alpha: relevance to genetic predisposition to systemic lupus erythematosus.

C O Jacob1, Z Fronek, G D Lewis, M Koo, J A Hansen, H O McDevitt.   

Abstract

We report on the production of tumor necrosis factor (TNF)-alpha and TNF-beta by mitogen-activated peripheral blood lymphocytes or enriched monocyte subpopulations from human leukocyte antigen (HLA)-typed healthy subjects. The results indicate that HLA-DR2- and DQw1-positive donors frequently exhibit low production of TNF-alpha, whereas DR3- and DR4-positive subjects show high levels of TNF-alpha production. No correlation between TNF-alpha levels and HLA-A, -B, and -C genotype was found. The relevance of this quantitative polymorphism to the genetic predisposition to lupus nephritis in systemic lupus erythematosus (SLE) patients was investigated. DR2, DQw1-positive SLE patients show low levels of TNF-alpha inducibility; this genotype is also associated with an increased incidence of lupus nephritis. DR3-positive SLE patients, on the other hand, are not predisposed to nephritis, and these patients have high TNF-alpha production. DR4 haplotype is associated with high TNF-alpha inducibility and is negatively correlated with lupus nephritis. These data may help explain the strong association between HLA-DR2, DQw1 in SLE patients and their susceptibility to nephritis.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2105500      PMCID: PMC53445          DOI: 10.1073/pnas.87.3.1233

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  23 in total

1.  Major histocompatibility complex associations with systemic lupus erythematosus.

Authors:  Z Fronek; L A Timmerman; C A Alper; B H Hahn; K Kalunian; B M Peterlin; H O McDevitt
Journal:  Am J Med       Date:  1988-12-23       Impact factor: 4.965

2.  Immunogenetics of systemic lupus erythematosus.

Authors:  J C Woodrow
Journal:  J Rheumatol       Date:  1988-02       Impact factor: 4.666

3.  Tumour necrosis factor and lymphotoxin genes map close to H-2D in the mouse major histocompatibility complex.

Authors:  U Müller; C V Jongeneel; S A Nedospasov; K F Lindahl; M Steinmetz
Journal:  Nature       Date:  1987 Jan 15-21       Impact factor: 49.962

4.  Glucocorticoids suppress the production of tumour necrosis factor by lipopolysaccharide-stimulated human monocytes.

Authors:  A Waage; O Bakke
Journal:  Immunology       Date:  1988-02       Impact factor: 7.397

5.  Genes for the tumor necrosis factors alpha and beta are linked to the human major histocompatibility complex.

Authors:  T Spies; C C Morton; S A Nedospasov; W Fiers; D Pious; J L Strominger
Journal:  Proc Natl Acad Sci U S A       Date:  1986-11       Impact factor: 11.205

Review 6.  Cachectin: more than a tumor necrosis factor.

Authors:  B Beutler; A Cerami
Journal:  N Engl J Med       Date:  1987-02-12       Impact factor: 91.245

Review 7.  Pathogenesis of systemic lupus erythematosus.

Authors:  A D Steinberg; D M Klinman
Journal:  Rheum Dis Clin North Am       Date:  1988-04       Impact factor: 2.670

8.  ELISA for quantitation of tumor necrosis factor-alpha in serum.

Authors:  W S Prince; K J Harder; S Saks; B R Reed; A B Chen; A J Jones
Journal:  J Pharm Biomed Anal       Date:  1987       Impact factor: 3.935

9.  Control of cachectin (tumor necrosis factor) synthesis: mechanisms of endotoxin resistance.

Authors:  B Beutler; N Krochin; I W Milsark; C Luedke; A Cerami
Journal:  Science       Date:  1986-05-23       Impact factor: 47.728

10.  Production of tumor necrosis factor/cachectin by human T cell lines and peripheral blood T lymphocytes stimulated by phorbol myristate acetate and anti-CD3 antibody.

Authors:  S S Sung; J M Bjorndahl; C Y Wang; H T Kao; S M Fu
Journal:  J Exp Med       Date:  1988-03-01       Impact factor: 14.307

View more
  122 in total

Review 1.  Tumour necrosis factor gene polymorphisms as severity markers in rheumatoid arthritis.

Authors:  C L Verweij
Journal:  Ann Rheum Dis       Date:  1999-11       Impact factor: 19.103

Review 2.  Unlinking tumor necrosis factor biology from the major histocompatibility complex: lessons from human genetics and animal models.

Authors:  S R Ruuls; J D Sedgwick
Journal:  Am J Hum Genet       Date:  1999-08       Impact factor: 11.025

Review 3.  Cytokines and systemic lupus erythematosus.

Authors:  G S Dean; J Tyrrell-Price; E Crawley; D A Isenberg
Journal:  Ann Rheum Dis       Date:  2000-04       Impact factor: 19.103

Review 4.  Prospects for the prevention and reversal of type 1 diabetes mellitus.

Authors:  Nikolai Petrovsky; Diego Silva; Desmond A Schatz
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 5.  [Tissue typing in perforating corneal transplantation].

Authors:  J Wachtlin; R Khaireddin; F Hoffmann
Journal:  Ophthalmologe       Date:  2003-12       Impact factor: 1.059

6.  Ulcerative colitis associated with aplastic anemia.

Authors:  Hiroshi Kishikawa; Jiro Nishida; Masaru Nakano; Erika Hirano; Tetsuo Morishita; Hiromasa Ishii
Journal:  Dig Dis Sci       Date:  2003-07       Impact factor: 3.199

Review 7.  Cytokine polymorphisms in silicosis and other pneumoconioses.

Authors:  Berran Yucesoy; Val Vallyathan; Douglas P Landsittel; Petia Simeonova; Michael I Luster
Journal:  Mol Cell Biochem       Date:  2002 May-Jun       Impact factor: 3.396

8.  Tumor necrosis factor-alpha gene promoter polymorphism in coal workers' pneumoconiosis.

Authors:  Kyoung Ah Kim; Yong-Yeun Cho; Jung Sik Cho; Ki Hwa Yang; Woon Kyu Lee; Kweon-Haeng Lee; Yun Shin Kim; Young Lim
Journal:  Mol Cell Biochem       Date:  2002 May-Jun       Impact factor: 3.396

9.  MHC class II, tumour necrosis factor alpha, and lymphotoxin alpha gene haplotype associations with serological subsets of systemic lupus erythematosus.

Authors:  N J McHugh; P Owen; B Cox; J Dunphy; K Welsh
Journal:  Ann Rheum Dis       Date:  2005-08-17       Impact factor: 19.103

10.  Polymorphism of tumour necrosis factor-alpha (TNF-alpha) at position -308 in relation to ankylosing spondylitis.

Authors:  G M Verjans; B M Brinkman; C E Van Doornik; A Kijlstra; C L Verweij
Journal:  Clin Exp Immunol       Date:  1994-07       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.